![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TQS-168 is a PGC-1a-enhancing small molecule in development for the treatment of neurodegenerative, metabolic, and aging-related diseases in which PGC-1a modulation plays a critical role.
Lead Product(s): TQS-168
Therapeutic Area: Neurology Product Name: TQS-168
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
TQS-168, a small molecule modulator of PGC-1a, for the treatment of amyotrophic lateral sclerosis (ALS). TQS-168 showed survival and functional benefits in various animal models of neurodegenerative disease, including ALS and Parkinson’s disease.
Lead Product(s): TQS-168
Therapeutic Area: Neurology Product Name: TQS-168
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The data from our Phase 1 study of TQS-168, a small molecule modulator of PGC-1a demonstrate that target plasma exposures can be achieved at dose levels that are well tolerated.
Lead Product(s): TQS-168
Therapeutic Area: Neurology Product Name: TQS-168
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
The financing will support company's novel platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorders.
Lead Product(s): TQS-168
Therapeutic Area: Neurology Product Name: TQS-168
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Remiges Ventures
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 09, 2020